Ophthalmology science · 2026
Intraocular Pressure-Lowering Therapy Slows Down Axial Elongation in Progressive High Myopia with Enhanced Choroidal Perfusion.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Zige, Yang Zefeng, Lin Fengbin, Jiang Jingwen, Wang Peiyuan, Kong Kangjie, Song Yunhe, Wang Deming, Liu Xiaoyi, Jiang Jiaxuan, Xie Bin, Xiaokaiti Dilimulati, Zhou Fengqi, Jin Ling, Chen Yu, Chen Meiling, Li Fei, Zhang Xiulan
Аннотация
PURPOSE: To evaluate the efficacy of intraocular pressure (IOP)-lowering medications in slowing down axial elongation among adults with progressive high myopia (PHM).
DESIGN: A retrospective longitudinal cohort study.
PARTICIPANTS: Fifty eyes from 50 adults with PHM (axial elongation ≥0.1 mm/year prior to using IOP-lowering medications) who initiated IOP-lowering medications at Zhongshan Ophthalmic Center between December 2019 and May 2025.
METHODS: A comprehensive set of variables, including demographic data, ocular characteristics, and OCT angiography imaging were collected and analyzed.
MAIN OUTCOME MEASURES: Change in the axial elongation rate before and after ≥12 months of IOP-lowering medication use.
RESULTS: Of the 1628 participants, 50 eyes from 50 eligible participants were finally analyzed. These participants had a mean age of 40.4 ± 10.7 years, with 72% being female; the mean number of IOP-lowering medications they used was 2.0 ± 0.3. After 12 months of follow-up, IOP decreased from 13.49 (2.50) to 12.03 (2.28) mmHg (P < 0.001). The axial elongation rate decreased from 0.14 (0.04) to 0.03 (0.07) mm/y (P < 0.001). OCT angiography showed increased perfusion density in the deep capillary plexus (DCP; 49.70% to 50.27%; P = 0.03) and choriocapillaris (CC; 55.47% to 55.66%; P = 0.04).
CONCLUSIONS: In this cohort, IOP-lowering therapy was associated with reduced axial elongation in adults with PHM, with concurrent modest enhancement of perfusion in DCP and CC. These findings support IOP-lowering therapy as a potential strategy to slow myopia progression in adults with PHM.
FINANCIAL DISCLOSURES: The authors have no proprietary or commercial interest in any materials discussed in this article.
DESIGN: A retrospective longitudinal cohort study.
PARTICIPANTS: Fifty eyes from 50 adults with PHM (axial elongation ≥0.1 mm/year prior to using IOP-lowering medications) who initiated IOP-lowering medications at Zhongshan Ophthalmic Center between December 2019 and May 2025.
METHODS: A comprehensive set of variables, including demographic data, ocular characteristics, and OCT angiography imaging were collected and analyzed.
MAIN OUTCOME MEASURES: Change in the axial elongation rate before and after ≥12 months of IOP-lowering medication use.
RESULTS: Of the 1628 participants, 50 eyes from 50 eligible participants were finally analyzed. These participants had a mean age of 40.4 ± 10.7 years, with 72% being female; the mean number of IOP-lowering medications they used was 2.0 ± 0.3. After 12 months of follow-up, IOP decreased from 13.49 (2.50) to 12.03 (2.28) mmHg (P < 0.001). The axial elongation rate decreased from 0.14 (0.04) to 0.03 (0.07) mm/y (P < 0.001). OCT angiography showed increased perfusion density in the deep capillary plexus (DCP; 49.70% to 50.27%; P = 0.03) and choriocapillaris (CC; 55.47% to 55.66%; P = 0.04).
CONCLUSIONS: In this cohort, IOP-lowering therapy was associated with reduced axial elongation in adults with PHM, with concurrent modest enhancement of perfusion in DCP and CC. These findings support IOP-lowering therapy as a potential strategy to slow myopia progression in adults with PHM.
FINANCIAL DISCLOSURES: The authors have no proprietary or commercial interest in any materials discussed in this article.